Approval of proposal to widen access to imiglucerase for type 1 and type 3 Gaucher disease
PHARMAC is pleased to announce the approval of a proposal to widen access to imiglucerase (Cerezyme) from 1 September 2013.
Approval of decisions involving boceprevir and pegylated interferon with/without ribavirin
PHARMAC is pleased to announce the approval of an agreement for the listing of boceprevir (Victrelis), and to amend the listing of pegylated interferon with/without ribavirin (Pegasys and Pegasys RBV Combination Pack).
Approval of proposal to remove the Special Authority from Arrow-Venlafaxine XR
PHARMAC is pleased to announce the approval of an agreement to remove the Special Authority and hospital restrictions from the Arrow-Venlafaxine XR brand of venlafaxine from 1 September 2013, in conjunction with a price decrease.
Proposal to list riluzole for the treatment of amyotrophic lateral sclerosis (motor neurone disease)
PHARMAC seeks feedback on a provisional agreement to fund riluzole (Rilutek) for the treatment of amyotrophic lateral sclerosis (ALS, also known as motor neurone disease). Closed: 5pm, Thursday, 22 August 2013.
100,000 people now with new meters
The change to new blood glucose testing meters has been completed, with more than 100,000 people picking up the new meters.
July 2013 tender notification
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2012/13 Invitation to Tender, dated 31 October 2012.
2013/14 invitation to tender (medical)
PHARMAC is seeking feedback from medical groups, DHB hospital pharmacies and other interested parties on: (1) A proposal to tender certain pharmaceuticals for sole supply; and (2) The draft process and terms and conditions for the 2013/14 Invitation to Tender (2013/14 Tender).
2013/14 invitation to tender (suppliers)
PHARMAC is seeking feedback from pharmaceutical suppliers and interested parties on: (1) a proposal to tender certain pharmaceuticals for sole supply; (2) the draft process and terms and conditions for the 2013/14 Invitation to Tender (2013/14 Tender); and (3) commercial proposals as an alternative to tendering.
Proposal to list boceprevir and amending the listing of pegylated interferon and ribavirin
PHARMAC is seeking feedback on a proposal to list boceprevir (Victrelis), and to amend the listing of pegylated interferon with/without ribavirin (Pegasys and Pegasys RBV Combination Pack).
Decisions involving diazepam, gabapentin, and naltrexone
PHARMAC is pleased to announce the approval of proposals relating to diazepam, gabapentin and naltrexone, which were the subject of a consultation letter dated 14 June 2013.
Approval of proposal to increase the price and subsidy for warfarin (Marevan)
PHARMAC is pleased to announce the approval of an agreement with GlaxoSmithKline NZ Limited relating to the supply of warfarin (Marevan). The price and subsidy for Marevan will be increased from 1 August 2013.
Clarification on bundle proposals – RFP for supply of various vaccines
PHARMAC has received a request in relation to this RFP from a supplier for clarification regarding PHARMAC’s willingness to consider bundle proposals up to a maximum of three bids with additional discounting for any other vaccine provided. In order to ensure all potential providers have access to the same information here is the clarification provided.
Proposal for a sole supply arrangement for fentanyl patches
PHARMAC is seeking feedback on a proposal to list a new brand of fentanyl patches, Fentanyl Sandoz, under a sole supply arrangement with Novartis New Zealand Limited. Closed: 5:00 pm, Monday, 22 July 2013.
First nationally-consistent list of hospital medicines takes effect
The national hospitals pharmaceutical list (HML) has been published for the first time on 1 July 2013. This brings nationally consistent access to subsidised pharmaceuticals into DHB hospitals.
June 2013 tender notification
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2012/13 Invitation to Tender, dated 31 October 2012.
RFP - Supply of various vaccines
PHARMAC invites proposals for the supply of various vaccines in New Zealand. Closed.
Proposal to widen access to imiglucerase for type 1 and type 3 Gaucher disease
PHARMAC is seeking feedback on a proposal to widen access to imiglucerase from 1 September 2013. Closed: Wednesday, 10 July 2013.
Proposal to increase the price and subsidy for warfarin (Marevan)
PHARMAC is seeking feedback on a proposal to increase the price and subsidy from 1 August 2013 for the Marevan brand of warfarin. Closed: Wednesday, 3 July 2013.
Approval of proposal to list preservative free eye drops and amend the listings related to other eye drops
PHARMAC has approved agreements with AFT Pharmaceuticals Ltd and with Alcon New Zealand Limited, regarding the listing of preservative free eye drops and the amending of listings related to other eye drops.
Approval of changes to listings of various products in the infections group
PHARMAC has approved a proposal to amend the listing of a number of products in the Infections Group of the Pharmaceutical Schedule from 1 July 2013.
Newsletters
Device Advice: Your update on PHARMAC’s Hospital Medical Devices programme.
Hospital News: News about getting the best value for what we spend on hospital pharmaceuticals.
Inpharmation: News about PHARMAC's activities and pharmaceutical-related issues.
Inpharmation in Hospitals: Hospital news about PHARMAC's activities and pharmaceutical-related issues.
Te Whaioranga ePānui: A PHARMAC newsletter for people with an interest in Māori health.
